secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001171843-21-005572
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex reports Q2 2021 net loss of $13.4M; raises $287.5M in follow-on offering
--------------------------------------------------------------------------------

- Net loss $13.4M ($0.34/share) vs $11.0M ($0.50/share) in Q2 2020; revenue $3.5M vs $0.2M.
- Cash $164.0M at June 30, 2021; July follow-on offering added $287.5M gross ($270M net), extending runway through 2025.
- CDX-0159 Phase 1b: 95% complete response in chronic inducible urticaria; 87% skin mast cell depletion with single dose.
- Plan to initiate CDX-0159 study in prurigo nodularis in Q4 2021 and subcutaneous formulation Phase 1 in Q3 2021.
- CDX-1140 expansion cohorts recruiting; CDX-527 dose escalation completed, expansion cohorts planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184321005572/0001171843-21-005572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184321005572/f8k_080521.htm
  HTML page:      https://secwatch.observer/filing/0001171843-21-005572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer